<SEC-DOCUMENT>0001104659-23-071653.txt : 20230615
<SEC-HEADER>0001104659-23-071653.hdr.sgml : 20230615
<ACCEPTANCE-DATETIME>20230615165659
ACCESSION NUMBER:		0001104659-23-071653
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230615
DATE AS OF CHANGE:		20230615

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26770
		FILM NUMBER:		231018177

	BUSINESS ADDRESS:	
		STREET 1:		21 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		21 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2318846d1_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Rule 14a-101)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INFORMATION REQUIRED IN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROXY STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE 14A INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Proxy Statement Pursuant to Section 14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Filed by the
Registrant </FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Filed by a
Party other than the Registrant </FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preliminary
Proxy Statement</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Definitive
Proxy Statement</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">x</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Definitive
Additional Materials</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
Material Pursuant to &sect;240.14a-12</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>NOVAVAX, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of registrant as specified in its charter)</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 0.75pt 1pt">&nbsp;</TD>
    <TD STYLE="padding: 0.75pt 1pt">&nbsp;</TD>
    <TD STYLE="padding: 0.75pt 1pt">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; padding-right: 1.25pt; padding-left: 1.25pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of person(s) filing proxy statement, if
other than the registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check all boxes that apply):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">x</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
fee required.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fee
paid previously with preliminary materials.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Novavax Announces
Adjournment of 2023 Annual Meeting of Stockholders to July 11, 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>GAITHERSBURG, Md.,
June 15, 2023 </B>&ndash; Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M<SUP>&trade;</SUP>
adjuvant, today announced that the Company has adjourned its 2023 Annual Meeting of Stockholders (the &ldquo;Annual Meeting&rdquo;), originally
scheduled to be held on June&nbsp;15, 2023, to July 11, 2023 at 8:30 a.m., Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On June 15, 2023 the
Company convened its Annual Meeting. At that time, there were not present in person virtually or by proxy a sufficient number of shares
of the Company&rsquo;s common stock to constitute a quorum. The presence in person virtually or by proxy of the holders of a majority
of the shares of the Company&rsquo;s common stock issued and outstanding on the record date and entitled to vote is required to constitute
a quorum at the Annual Meeting. Accordingly, the Company adjourned the Annual Meeting without any business being conducted. The adjourned
meeting will reconvene on July 11, 2023 at 8:30 a.m., Eastern Time, as a virtual meeting at www.virtualshareholdermeeting.com/NVAX2023,
to vote on the proposals described in the Definitive Proxy Statement filed by the Company with the Securities and Exchange Commission
(the &ldquo;SEC&rdquo;) on April 28, 2023 (as amended by Amendment No. 1 filed with the SEC on May 3, 2023, the &ldquo;Proxy Statement&rdquo;).
The record date as of the close of business on April&nbsp;18, 2023 remains unchanged for the determination of stockholders of the Company
entitled to notice of and to vote at the reconvened Annual Meeting and any adjournments or postponements thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the period of
adjournment, the Company and its proxy solicitor, MacKenzie Partners, Inc., will continue to solicit votes from the Company&rsquo;s stockholders
with respect to the proposals set forth in the Proxy Statement. <FONT STYLE="color: #231F20; background-color: white">At the time the
Annual Meeting was adjourned, proxies had been submitted by holders representing 49.3% of the shares of the Company&rsquo;s common stock
issued and outstanding on the record date and entitled to vote at the Annual Meeting.&nbsp;</FONT>Proxies previously submitted in respect
of the Annual Meeting will be voted at the adjourned meeting unless properly revoked.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">No changes have been
made to the proposals to be voted on by stockholders at the Annual Meeting. The Company urges all of its stockholders to read the Proxy
Statement and other proxy materials relating to the Annual Meeting, which are available free of charge on the SEC&rsquo;s website at
<FONT STYLE="color: Blue"><U>www.sec.gov</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Novavax</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Novavax, Inc. (Nasdaq: NVAX) promotes improved
health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a
global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach,
innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world&rsquo;s
most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined.
Please visit <FONT STYLE="color: #0563C1"><U>novavax.com</U></FONT> and <FONT STYLE="color: Blue"><U>LinkedIn</U></FONT> for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Investors</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Erika Schultz | 240-268-2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Blue"><U>ir@novavax.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Media</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ali Chartan | 240-720-7804</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Blue"><U>media@novavax.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>








</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( *,# 2(  A$! Q$!_\0
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MU+5_B*+K3[<?V3?R))=2AU'DG/[S@G)SC/'=J]K@@CMK>."% D42A$4= H&
M*JI*-O=ZBBG?7H>(?#01M\9/$C7^/MP-QY>[KGS?FQ[[<?AFO<'"%"),%"#D
M-TQWS7E/CWX=ZR?$B>+?"$FS4<AIH0P5BP&-RD\'(X*GK^-4U'Q7\70?V5?P
M0:-92#9<W6P([(>H #$\CTQ]:4TIVDF"=M"C\$! /&'B06W_ ![A/W6/[GF-
MM_3%6/BU9S>&?&6C>-;%#_K%2?'=UZ9_WDW+^%:7PG\%ZUX5\0:Q)J-FT-K)
M&([>0R(=X#G'"DXXP:[GQKX>7Q/X2O\ 2\#SI$W0,?X95Y4_F,?0FG*:56_0
M$O=/,/'-\OQ$\=Z!X8TZ4O8*JW,[KZ.H8G\$X^K5T'QMB-O\.H(+9-D"7D*%
M5Z! K8'TR%J+X0^ K_PT;_4]:M1!?38AAC+JQ6/J3D$CDX_[YKT'Q!H=IXCT
M*[TF]!\FX3:6'5#U##W!P:4I*,TEL@2;3\S+^'BVB_#[0A9X\K[(A./[W\?X
M[LUQ/Q]6U_X1G2V?'VL7;"+UV[#O_#[OZ5C:9I7Q/^'TLNGZ1:1ZIIS.63 #
MQ\]P"P9#ZCI5;Q/X!^(/B:SCU;5@ESJ+/Y<=C$Z*L$6"2>N,DXX!)]351BE/
MFOH)MN-K'M7AG_D4]'_Z\8?_ $ 5\\?%%=,@\=W_ /PCS2JYB;[>(?N"0\.!
MCL1C=VR:]HUD^)M.^']C8:!I[2ZN;6.W9A(BBWP@#-DGD]ACOS5'X<_#R+PY
MH-PVKPI/J>HH5NPYWA8S_P L\]_4GN?H*FG)0;DQM7T+GPK.B_\ ""60T4G:
M/^/G?C?Y_P#'NQ^GMBNU;)4XQG'&:\>T3PAXG\ >/)I-#LWU#PY=,!*@F0,J
M$\<,1ED]>XKUZ8R>1(80IEVG8'X&<<9]JSJ)7NGN5'8XV#3OB$(L2ZYI._<W
M6V)XR<=,=L45UFG->MIT#:DD*7I0><L!)0-[$\XHH]H^R^XHM4445 !1110
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LLZ<8JU_NL7-/TVUTNV-O9Q>7$7+[<D\GKUJY116Z22LCF;;=V%%%%,1__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
